3 articles · Updated · The Associated Press · Aug 20
Summary
WHO and partners said 70,000 Ervebo doses will be released immediately to Congo after a government request, marking a major reinforcement for efforts to curb the country's fastest-ever Ebola outbreak.
20,000 doses will go to a Phase 3 trial testing whether Ervebo can protect against the Bundibugyo virus, while 50,000 are earmarked for frontline and health workers.
The current outbreak has caused 2,476 deaths from 5,208 confirmed cases across six eastern provinces, with WHO saying it is spreading about three times faster than the 2014-2016 West Africa epidemic.
Response teams still face a major gap because no vaccine or treatment is approved for Bundibugyo, and many new infections are being found outside monitored contacts; the fatality rate is 47.5% overall and up to 70% in North Kivu.
Can an unproven vaccine stop history's fastest Ebola outbreak before it escapes Congo's dangerous conflict zones?
What happens if the experimental Ervebo vaccine fails to protect frontline workers against the deadly Bundibugyo virus?
Ebola in 2026: Bundibugyo Strain Sparks Deadliest DRC Outbreak, Testing Global Health Preparedness
Overview
The 2026 Bundibugyo Ebola outbreak in eastern DRC rapidly escalated due to years of violence, mass displacement, and overcrowded camps, which fueled virus transmission. Security incidents and attacks on health facilities restricted medical access and disrupted surveillance, allowing the virus to spread undetected across borders. Deep funding cuts dismantled frontline health networks, leaving communities vulnerable. The lack of government control in conflict zones, combined with mistrust over burial practices and strikes by unpaid healthcare workers, further undermined containment. As scarce resources shifted to Ebola, routine health services collapsed, especially for women and children, risking a devastating secondary health crisis.